Literature DB >> 22529721

Anti-retroviral strategies for AIDS and related diseases.

M A Wainberg1, A Dascal, J Mendelson.   

Abstract

The replication cycle of human immunodeficiency virus type 1 (HIV-1) and other retroviruses consists of four stages: attachment of the virus to specific receptors on the cell surface; uncoating of the viral nucleic acid and conversion to DNA; production of viral RNA and proteins; and assembly and liberation of progeny virus from the cell. Each of these steps represents a potential target for antiviral chemotherapy. Combinations of drugs which act against different steps in the viral replication cycle might be expected to have synergistic potential. Zidovudine (AZT) is the most widely used drug to date for impeding the replication of HIV-1. Although AZT therapy has been reasonably successful, it has not been free from toxicity. In addition, there have been several reports of isolation of AZT-resistant variants of HIV-1.

Entities:  

Keywords:  AIDS; HIV-1; Therapy; Viral replication; Zidovudine

Year:  1991        PMID: 22529721      PMCID: PMC3328006          DOI: 10.1155/1991/487657

Source DB:  PubMed          Journal:  Can J Infect Dis        ISSN: 1180-2332


  38 in total

1.  Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine.

Authors:  B D Walker; M Kowalski; W C Goh; K Kozarsky; M Krieger; C Rosen; L Rohrschneider; W A Haseltine; J Sodroski
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

Review 2.  The management of the neurological complications of HIV infection and AIDS.

Authors:  H A Aronow; B J Brew; R W Price
Journal:  AIDS       Date:  1988       Impact factor: 4.177

3.  An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation.

Authors:  J T Holt; R L Redner; A W Nienhuis
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

4.  Cessation of zidovudine therapy may lead to increased replication of HIV-1.

Authors:  M A Wainberg; J Falutz; M Fanning; J Gill; K Gelmon; J S Montaner; M O'Shaughnessy; C Tsoukas; J Ruedy
Journal:  JAMA       Date:  1989-02-10       Impact factor: 56.272

5.  Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives.

Authors:  R Pauwels; K Andries; J Desmyter; D Schols; M J Kukla; H J Breslin; A Raeymaeckers; J Van Gelder; R Woestenborghs; J Heykants
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

Review 6.  The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex.

Authors:  R W Price; B Brew; J Sidtis; M Rosenblum; A C Scheck; P Cleary
Journal:  Science       Date:  1988-02-05       Impact factor: 47.728

7.  HIV-specific cytotoxic T lymphocytes in seropositive individuals.

Authors:  B D Walker; S Chakrabarti; B Moss; T J Paradis; T Flynn; A G Durno; R S Blumberg; J C Kaplan; M S Hirsch; R T Schooley
Journal:  Nature       Date:  1987 Jul 23-29       Impact factor: 49.962

8.  The antiviral effect of zidovudine and ribavirin in clinical trials and the use of p24 antigen levels as a virologic marker.

Authors:  S A Spector; C Kennedy; J A McCutchan; S A Bozzette; R G Straube; J D Connor; D D Richman
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

9.  Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase.

Authors:  R A Gruters; J J Neefjes; M Tersmette; R E de Goede; A Tulp; H G Huisman; F Miedema; H L Ploegh
Journal:  Nature       Date:  1987 Nov 5-11       Impact factor: 49.962

10.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.